Table of Contents
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs.
“Today’s White House listening session on PBMs, where policymakers only hear from people and groups with vocal anti-PBM agendas, will make for a biased and unproductive discussion. The PBM market is diverse and competitive, giving employers and plan sponsors choice and flexibility in managing prescription drug costs. Unfortunately, today’s event serves to promote only one model and one perspective. We share the Administration’s goal of lowering prescription drug costs and would welcome the opportunity to work together to make prescription drugs more affordable for patients and employers.
“Rather than take the bait from Big Pharma and those with self-serving agendas, policymakers should hear directly from the PBMs who are actually negotiating against Big Pharma to lower drug costs. America’s pharmacy benefit companies save patients and payers more than $1,000 each year, fulfilling our primary mission to reduce prescription drug costs for patients and employers. In addition, PBMs support a diverse market that allows different PBMs to compete and offer different models, along with transparency that empowers prescribers, plan sponsors, policymakers, and, most importantly, patients, with the information they need to lower costs while improving access to needed medications.”
